SP 600125
Alternative Names: SP600125Latest Information Update: 19 Dec 2008
At a glance
- Originator Signal Research Division
- Class Antirheumatics
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors; Mitogen-activated protein kinase 8 inhibitors; Mitogen-activated protein kinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allotransplant rejection; Asthma; Cancer; Cerebral ischaemia; Rheumatoid arthritis
Most Recent Events
- 05 Feb 2008 No development reported - Preclinical for Allotransplant rejection in USA (unspecified route)
- 05 Feb 2008 No development reported - Preclinical for Cerebral ischaemia in China (unspecified route)
- 20 Oct 2005 Preclinical trials in Cerebral ischaemia in China (unspecified route)